Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Helius Medical Technologies, Inc.

A neurotech company focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

Helius Medical Technologies

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS).

PoNS™, short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait.

PoNS is authorized in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

PoNS is authorized in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. 

PoNS is authorized in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

PoNS™ (ponstherapy.com), short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait.

Studies have shown that individuals with multiple sclerosis who completed 14-weeks of PoNS Therapy® (www.ponstherapy.com) have seen improvements in their gait scores of an average of 8 points. 

An 8-point improvement in your gait can mean improving your walking so you can RSVP “yes” to the wedding, book the vacation you have been putting off, or go for a walk on the beach. 

Learn more at www.ponstherapy.com.

Individual results and experiences may vary. Speak to your physician to determine if PoNS is right for you.

After 14-weeks of PoNS Therapy® (www.ponstherapy.com), 100% of participants with multiple sclerosis saw a 
4-point improvement in dynamic gait index (DGI) scores, with an average of almost 8 points and 40% even saw improvements above 8 points. 

We encourage you to set your sights high – AIM FOR EIGHT points of improvement. 

Learn more: https://lnkd.in/e6Ja8tva

Individual results and experiences may vary. Speak to your physician to determine if PoNS® is right for you. 

#PoNS #PoNSTherapy #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #MultipleSclerosis #MS #PhysicalRehabilitation #Walking

PoNS® (www.ponstherapy.com) is committed to improving walking ability across the country.  

Keep an eye out—we hope to bring PoNS to those in the US with gait deficit due to stroke soon.

Learn more: https://lnkd.in/eWPe7Tuy

#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #MultipleSclerosis #MS #PhysicalRehabilitation #Walking #Stroke

PoNS® (www.ponstherapy.com) proudly supports our Veterans!

Discover how we're dedicated to helping Veterans with multiple sclerosis improve their gait on our new page. 

Learn more today: https://lnkd.in/eTb9Zfwf

#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #GetBackInStepWithLife #PhysicalTherapy #MS #MultipleSclerosis #Veterans #VA #USVeterans #Vet

After using PoNS™ (www.ponstherapy.ca) for 14 weeks, 28% of people with stroke were no longer at fall risk. Routine physical therapy usually only provides a meaningful shift in fall risk for 1-3% of patients. 

Learn more about PoNS Therapy™: www.ponstherapy.ca

Individual results and experiences vary. Patients should talk to their doctor to see if PoNS is right for them. 


#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #TraumaticBrainInjury #TBI #Stroke #MultipleSclerosis #MS #PhysicalRehabilitation #Walking #Neurostimulation #FallRisk

	Mar '14	Mar '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover					0.02 -	0.14 741.70%	0.10 30.17%	0.04 63.34%	0.05 22.99%	0.08 83.90%
cash conversion cycle						-325.05 -	-209.77 35.46%	-550.82 162.58%	129.12 123.44%	324.78 151.53%
cash per share	0.00 -	2.44 9,794,255.09%	5.60 129.22%	10.45 86.45%	39.30 276.12%	7.25 81.55%	2.78 61.64%	4.48 61.07%	1.08 75.94%	8.52 690.83%
company equity multiplier	1 -	-0.78 177.83%	-1.00 28.72%	-0.91 9.25%	2.82 410.64%	1.77 37.21%	1.69 4.62%	1.25 25.92%	2.12 69.28%	3.27 54.33%
days of inventory outstanding						258.00 -	365.94 41.84%	583.02 59.32%	464.33 20.36%	223.90 51.78%
days of payables outstanding						723.10 -	702.72 2.82%	1.31K 86.33%	494.29 62.25%	260.15 47.37%
days of sales outstanding					209.99 -	140.05 33.31%	127.00 9.31%	175.51 38.19%	159.08 9.36%	361.03 126.95%
dividend yield
ebit per revenue					-55.81 -	-16.04 71.26%	-21.76 35.68%	-34.75 59.69%	-18.75 46.04%	-19.05 1.59%
ebt per ebit	1 -	1.00 0.34%	1.16 15.67%	1.23 5.66%	1.07 12.50%	0.41 62.01%	0.98 140.97%	1.00 1.76%	0.95 4.60%	0.72 24.35%
effective tax rate		0.02 -	-0.14 939.45%	-0.37 166.70%	-0.14 62.52%	1.44 1,143.71%	0.01 99.05%	0.00 95.96%	0.11 19,408.14%
enterprise value multiple	-6.39K -	-807.49 87.37%	-667.72 17.31%	-649.42 2.74%	-423.10 34.85%	-33.57 92.06%	-55.83 66.28%	-34.90 37.48%	-11.98 65.68%	0.02 100.16%
fixed asset turnover					0.86 -	1.18 37.17%	1.15 3.04%	1.27 10.41%	1.75 38.03%	2.80 60.10%
free cash flow per share	-0.97 -	-19.39 1,905.28%	-16.55 14.63%	-36.66 121.44%	-30.81 15.94%	-28.36 7.97%	-9.86 65.24%	-5.47 44.49%	-1.06 80.60%	-17.18 1,518.72%
gross profit margin					1 -	0.43 56.55%	0.41 4.94%	0.43 3.90%	0.41 4.06%	-0.16 138.09%
interest coverage		-50.23 -	-6.23 87.60%	-4.42 29.03%	-13.69 209.85%				-17.70 -	-47.74 169.76%
inventory turnover						1.41 -	1.00 29.50%	0.63 37.23%	0.79 25.56%	1.63 107.38%
long term debt to capitalization						0.07 -	0.01 88.89%		0.01 -	0.01 25.54%
net income per ebt	1 -	1 0%	1 0%	1 0%	1 0%	-0.44 144.36%	0.99 322.34%	1.00 1.33%	0.89 10.71%	1 12.06%
net profit margin					-59.88 -	2.90 104.84%	-21.08 826.96%	-34.72 64.65%	-15.96 54.04%	-13.74 13.88%
operating cash flow per share	-0.97 -	-19.39 1,905.28%	-16.55 14.63%	-36.30 119.28%	-30.14 16.98%	-27.89 7.46%	-9.80 64.86%	-5.45 44.39%	-1.06 80.54%	-17.13 1,516.14%
operating cycle						398.05 -	492.95 23.84%	758.53 53.88%	623.41 17.81%	584.93 6.17%
operating profit margin					-55.81 -	-16.04 71.26%	-21.76 35.68%	-34.75 59.69%	-18.75 46.04%	-19.05 1.59%
payables turnover						0.50 -	0.52 2.90%	0.28 46.33%	0.74 164.90%	1.40 90.00%
pretax profit margin					-59.88 -	-6.54 89.08%	-21.38 226.96%	-34.74 62.49%	-17.88 48.52%	-13.74 23.14%
price fair value	757.95M -	-4.57K 100.00%	-1.67K 63.51%	-1.53K 8.11%	1.06K 169.11%	219.04 79.32%	204.14 6.80%	56.64 72.25%	25.42 55.12%	2.08 91.82%
receivables turnover					1.74 -	2.61 49.94%	2.87 10.27%	2.08 27.64%	2.29 10.33%	1.01 55.94%
return on assets	-118.59K -	-7.31 99.99%	-3.49 52.28%	-4.12 17.93%	-1.03 75.01%	0.42 140.77%	-2.13 607.64%	-1.29 39.63%	-0.73 43.47%	-1.15 58.38%
return on capital employed	-118.59K -	-478.06 99.60%	3.01 100.63%	3.05 1.29%	-2.71 188.72%	-3.67 35.44%	-3.49 4.83%	-1.58 54.59%	-0.96 39.12%	-2.11 118.78%
return on equity	-118.59K -	5.69 100.00%	3.50 38.57%	3.74 7.02%	-2.90 177.63%	0.74 125.60%	-3.60 584.17%	-1.61 55.28%	-1.54 4.31%	-3.77 144.44%
total debt to capitalization				-0.16 -		0.10 -	0.02 76.66%	0.00 98.84%	0.01 4,897.34%	0.02 77.84%

COM:HELIUSMEDICAL

Helius Medical Technologies

Last Close

0.47

21/11 21:00

Market Cap

2.54M

Beta: -

Volume Today

57.45K

Avg: -

Preview